Page 49 - AN-3-1

Advanced Neurology Antibodies as neurodegenerative biomarkers

vaccine development. Neuromolecular Med. 2003;3(1):29-30. doi: 10.1016/j.jneuroim.2010.12.001
doi: 10.1385/NMM:3:1:29 111. Akhtar RS, Licata JP, Luk KC, Shaw LM, Trojanowski JQ,
Lee VM. Measurements of auto-antibodies to α-synuclein
101. Maftei M, Thurm F, Schnack C, et al. Increased levels of in the serum and cerebral spinal fluids of patients with
antigen-bound β-amyloid autoantibodies in serum and Parkinson’s disease. J Neurochem. 2018;145(6):489-503.
cerebrospinal fluid of Alzheimer’s disease patients. PLoS
One. 2013;8(7):e68996. doi: 10.1111/jnc.14330
doi: 10.1371/journal.pone.0068996 112. Maetzler W, Apel A, Langkamp M, et al. Comparable
autoantibody serum levels against amyloid- and
102. Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ, et al. inflammation-associated proteins in Parkinson’s disease
Dissociated amyloid-β antibody levels as a serum biomarker patients and controls. PLoS One. 2014;9(2):e88604.
for the progression of Alzheimer’s disease: A population-
based study. Exp Gerontol. 2010;45(1):47-52. doi: 10.1371/journal.pone.0088604
doi: 10.1016/j.exger.2009.10.003 113. Smith LM, Schiess MC, Coffey MP, Klaver AC, Loeffler DA.
α-Synuclein and anti-α-synuclein antibodies in Parkinson’s
103. Bartos A, Fialová L, Švarcová J. Lower serum antibodies disease, atypical Parkinson syndromes, REM sleep behavior
against tau protein and heavy neurofilament in Alzheimer’s disorder, and healthy controls. PLoS One. 2012;7(12):e52285.
disease. J Alzheimers Dis. 2018;64(3):751-760.
doi: 10.1371/journal.pone.0052285
doi: 10.3233/JAD-180039
114. Besong-Agbo D, Wolf E, Jessen F, et al. Naturally occurring
104. Krestova M, Ricny J, Bartos A. Changes in concentrations of α-synuclein autoantibody levels are lower in patients with
tau-reactive antibodies are dependent on sex in Alzheimer’s Parkinson disease. Neurology. 2013;80(2):169-175.
disease patients. J Neuroimmunol. 2018;322:1-8.
doi: 10.1212/WNL.0b013e31827b90d1
doi: 10.1016/j.jneuroim.2018.05.004
115. Tzartos JS, Zisimopoulou P, Rentzos M, et al. LRP4
105. Klaver AC, Coffey MP, Bennett DA, Loeffler DA. Specific antibodies in serum and CSF from amyotrophic lateral
serum antibody binding to phosphorylated and non- sclerosis patients. Ann Clin Transl Neurol. 2014;1(2):80-87.
phosphorylated tau in non-cognitively impaired, mildly
cognitively impaired, and Alzheimer’s disease subjects: An doi: 10.1002/acn3.26
exploratory study. Transl Neurodegener. 2017;6(1):32. 116. Fialová L, Švarcová J, Bartos A, et al. Cerebrospinal fluid and
doi: 10.1186/s40035-017-0100-x serum antibodies against neurofilaments in patients with
amyotrophic lateral sclerosis. Eur J Neurol. 2010;17(4):562-566.
106. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren
L, Morozova-Roche LA. α-Synuclein reactive antibodies as doi: 10.1111/j.1468-1331.2009.02853.x
diagnostic biomarkers in blood sera of Parkinson’s disease 117. Messer A, Butler DC. Optimizing intracellular antibodies
patients. PLoS One. 2011;6(4):e18513. (intrabodies/nanobodies) to treat neurodegenerative
doi: 10.1371/journal.pone.0018513 disorders. Neurobiol Dis. 2020;134:104619.
107. Shalash A, Salama M, Makar M, et al. Elevated serum doi: 10.1016/J.NBD.2019.104619
α-synuclein autoantibodies in patients with parkinson’s 118. Asefy Z, Hoseinnejhad S, Ceferov Z. Nanoparticles
disease relative to Alzheimer’s disease and controls. Front approaches in neurodegenerative diseases diagnosis and
Neurol. 2017;8:720. treatment. Neurol Sci. 2021;42(7):2653-2660.
doi: 10.3389/fneur.2017.00720 doi: 10.1007/S10072-021-05234-X

108. Xu Q, Evetts S, Hu M, Talbot K, Wade-Martins R, Davis JJ. 119. Van Dyck CH. Anti-amyloid-β monoclonal antibodies for
An impedimetric assay of α-synuclein autoantibodies in early Alzheimer’s disease: Pitfalls and promise. Biol Psychiatry.
stage Parkinson’s disease. RSC Adv. 2014;4(102):58773-58777. 2018;83(4):311-319.
doi: 10.1039/c4ra10100f doi: 10.1016/j.biopsych.2017.08.010
109. Bryan T, Luo X, Forsgren L, Morozova-Roched LA, Davis JJ. 120. Arndt JW, Qian F, Smith BA, et al. Structural and kinetic
The robust electrochemical detection of a Parkinson’s disease basis for the selectivity of aducanumab for aggregated forms
marker in whole blood sera. Chem Sci. 2012;3(12):3468-3473. of amyloid-β. Sci Rep. 2018;8(1):6412.
doi: 10.1039/c2sc21221h doi: 10.1038/s41598-018-24501-0
110. Gruden MA, Sewell RDE, Yanamandra K, et al. 121. Lu M, Brashear HR. Pharmacokinetics, pharmacodynamics,
Immunoprotection against toxic biomarkers is retained and safety of subcutaneous bapineuzumab: A single-ascending-
during Parkinson’s disease progression. J Neuroimmunol. dose study in patients with mild to moderate Alzheimer disease.
2011;233(1-2):221-227. Clin Pharmacol Drug Dev. 2019;8(3):326-335.

Volume 3 Issue 1 (2024) 14 https://doi.org/10.36922/an.2058